EvlaBio Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$24.4M
- Investors
-
7
EvlaBio General Information
Description
Developer of targeted monoclonal antibody-based therapeutics intended for the treatment of left ventricular hypertrophy in chronic kidney disease patients. The company is advancing a monoclonal antibody that blocks harmful signaling in heart muscle cells while preserving beneficial hormone activity, reducing pathological cardiac remodeling and fibrosis, and supporting healthier heart structure and function, enabling chronic kidney disease patients to address severe cardiorenal complications with a more precise, mechanism-driven therapy.
Contact Information
Website
www.evlabio.comCorporate Office
- C/O ARQIS
- Breite Straße 28
- 40213 Düsseldorf
- Germany
Corporate Office
- C/O ARQIS
- Breite Straße 28
- 40213 Düsseldorf
- Germany
EvlaBio Timeline
EvlaBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Seed Round | 07-Jul-2025 | $24.4M | Completed | Generating Revenue | ||
| 1. Seed Round | 13-Sep-2022 | Completed | Generating Revenue |
EvlaBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred Shares |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
EvlaBio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
EvlaBio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
EvlaBio Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AdBio partners | Venture Capital | Minority | ||
| Boehringer Ingelheim Venture Fund | Corporate Venture Capital | Minority | ||
| High-Tech Gründerfonds | Venture Capital | Minority | ||
| Khanu Management | Venture Capital | Minority | ||
| Kurma Partners | Venture Capital | Minority |
EvlaBio FAQs
-
When was EvlaBio founded?
EvlaBio was founded in 2022.
-
Where is EvlaBio headquartered?
EvlaBio is headquartered in Düsseldorf, Germany.
-
What is the size of EvlaBio?
EvlaBio has 7 total employees.
-
What industry is EvlaBio in?
EvlaBio’s primary industry is Drug Discovery.
-
Is EvlaBio a private or public company?
EvlaBio is a Private company.
-
What is EvlaBio’s current revenue?
The current revenue for EvlaBio is .
-
How much funding has EvlaBio raised over time?
EvlaBio has raised $24.6M.
-
Who are EvlaBio’s investors?
AdBio partners, Boehringer Ingelheim Venture Fund, High-Tech Gründerfonds, Khanu Management, and Kurma Partners are 5 of 7 investors who have invested in EvlaBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
